Home /
Treatment Details – 15.0 months
|
|
Description: |
Patients: This Phase II study involved 31 patients with malignant pleural mesothelioma. Treatment: The treatment consisted of the injection of human recombinant Interleukin-2 (Proleukin). Toxicity: Grade 3 toxicities included cardiac failure and fever. Grade 2 toxicities included neuropathy, neurologic, and gastrointestinal. Results: Median overall survival was 15 months. Correspondence: Bruno Castagneto, MD |